Specified clinical trial on the efficacy and safety of auranofin for desmoid-type fibromatosis - Auranofin clinical trial for desmoid (ACTD)

ishida Yoshihiro0 sites23 target enrollmentSeptember 16, 2021

Overview

No summary available.

Registry

who.int

Start Date

September 16, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

ishida Yoshihiro

•Pathologically diagnosed with desmoid
•Aged 18 years or older at the time of consent
•With evaluable lesions (tumors)
•With tumor progression within 6 months prior to the start of the trial, or patients who are inoperable
•Written consent has been obtained by the person (and the surrogate)
•With ECOG PS of 0 or 1 on observation within 14 days prior to enrollment
•Test results within 14 days before enrollment meet the following criteria and have sufficient organ function
•White blood cell count more than 3,000 / mm3
•Number of neutrophils more than 1,500 / mm3
•Hemoglobin more than 9\.0 g / dL

•Patients contraindicated in the auranofin package insert
•Patients comparable to important basic precautions in the auranofin package insert
•Patients taking auranofin within 4 weeks prior to consent
•Patients who took anti\-cancer drugs or targeted therapies within 4 weeks before obtaining consent
•Patients who are judged by the investigator to be ineligible for enrollment in the clinical trial
•Patients who are unsuitable for MRI, CT, etc.
•Patients who have difficulty taking oral medications